Global N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11240196

Publication Date:

November 4, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

N-Acetylglutamate Synthase Deficiency (NAGS Deficiency) is a rare inherited metabolic disorder and a member of the urea cycle disorders (UCDs). The urea cycle converts toxic ammonia in the body into non-toxic urea, which is excreted from the body through the kidneys.
The global N-Acetylglutamate Synthetase Deficiency (NAGSD) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淣-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Forecast鈥� looks at past sales and reviews total world N-Acetylglutamate Synthetase Deficiency (NAGSD) sales in 2022, providing a comprehensive analysis by region and market sector of projected N-Acetylglutamate Synthetase Deficiency (NAGSD) sales for 2023 through 2029. With N-Acetylglutamate Synthetase Deficiency (NAGSD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world N-Acetylglutamate Synthetase Deficiency (NAGSD) industry.
This Insight Report provides a comprehensive analysis of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on N-Acetylglutamate Synthetase Deficiency (NAGSD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global N-Acetylglutamate Synthetase Deficiency (NAGSD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for N-Acetylglutamate Synthetase Deficiency (NAGSD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global N-Acetylglutamate Synthetase Deficiency (NAGSD).
United States market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key N-Acetylglutamate Synthetase Deficiency (NAGSD) players cover Recordati Rare Diseases, Grand Pharmaceutical Group, Sovereign Medical, Lee's Pharmaceuticals, Medunik, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of N-Acetylglutamate Synthetase Deficiency (NAGSD) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Original Drug
Generic Drug
Segmentation by Application:
Adults
Children
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Original Drug
Generic Drug
Segmentation by Application:
Adults
Children
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Recordati Rare Diseases
Grand Pharmaceutical Group
Sovereign Medical
Lee's Pharmaceuticals
Medunik
Acer Therapeutics
Sigmapharm Laboratories
Amgen
Immedica

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size 2019-2030
2.1.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for N-Acetylglutamate Synthetase Deficiency (NAGSD) by Country/Region, 2019, 2023 & 2030
2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Type
2.2.1 Original Drug
2.2.2 Generic Drug
2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Type
2.3.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Application
2.4.1 Adults
2.4.2 Children
2.5 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Application
2.5.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Player
3.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Player (2019-2024)
3.1.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 N-Acetylglutamate Synthetase Deficiency (NAGSD) by Region
4.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Region (2019-2024)
4.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Annual Revenue by Country/Region (2019-2024)
4.3 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size Growth (2019-2024)
4.4 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size Growth (2019-2024)
4.5 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Country (2019-2024)
5.2 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Type (2019-2024)
5.3 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Region (2019-2024)
6.2 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Type (2019-2024)
6.3 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Country (2019-2024)
7.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Type (2019-2024)
7.3 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) by Region (2019-2024)
8.2 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Forecast
10.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Region (2025-2030)
10.1.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Region (2025-2030)
10.1.2 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.1.3 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.1.4 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.1.5 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.2 Americas N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.2.2 Canada 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.2.3 Mexico 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.2.4 Brazil 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.3 APAC N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Region (2025-2030)
10.3.1 China N-Acetylglutamate Synthetase Deficiency (NAGSD) 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.3.3 Korea 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.3.4 Southeast Asia 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.3.5 India 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.3.6 Australia 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.4 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.4.2 France 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.4.3 UK 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.4.4 Italy 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.4.5 Russia 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.5 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.5.2 South Africa 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.5.3 Israel 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.5.4 Turkey 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
10.6 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Type (2025-2030)
10.7 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecast
11 Key Players Analysis
11.1 Recordati Rare Diseases
11.1.1 Recordati Rare Diseases Company Information
11.1.2 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.1.3 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Recordati Rare Diseases Main Business Overview
11.1.5 Recordati Rare Diseases Latest Developments
11.2 Grand Pharmaceutical Group
11.2.1 Grand Pharmaceutical Group Company Information
11.2.2 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.2.3 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Grand Pharmaceutical Group Main Business Overview
11.2.5 Grand Pharmaceutical Group Latest Developments
11.3 Sovereign Medical
11.3.1 Sovereign Medical Company Information
11.3.2 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.3.3 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Sovereign Medical Main Business Overview
11.3.5 Sovereign Medical Latest Developments
11.4 Lee's Pharmaceuticals
11.4.1 Lee's Pharmaceuticals Company Information
11.4.2 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.4.3 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Lee's Pharmaceuticals Main Business Overview
11.4.5 Lee's Pharmaceuticals Latest Developments
11.5 Medunik
11.5.1 Medunik Company Information
11.5.2 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.5.3 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Medunik Main Business Overview
11.5.5 Medunik Latest Developments
11.6 Acer Therapeutics
11.6.1 Acer Therapeutics Company Information
11.6.2 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.6.3 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Acer Therapeutics Main Business Overview
11.6.5 Acer Therapeutics Latest Developments
11.7 Sigmapharm Laboratories
11.7.1 Sigmapharm Laboratories Company Information
11.7.2 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.7.3 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Sigmapharm Laboratories Main Business Overview
11.7.5 Sigmapharm Laboratories Latest Developments
11.8 Amgen
11.8.1 Amgen Company Information
11.8.2 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.8.3 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Amgen Main Business Overview
11.8.5 Amgen Latest Developments
11.9 Immedica
11.9.1 Immedica Company Information
11.9.2 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Offered
11.9.3 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Immedica Main Business Overview
11.9.5 Immedica Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.